Independent 5-year pharmaceutical and healthcare industry forecasts for Egypt.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Egyptian pharmaceutical and healthcare industry.
Competitive intelligence, Egyptian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Egyptian market.
The Egypt Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’
Key Benefits of Report
Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Egypt to test other views – a key input for successful budgeting and strategic business planning in the Egyptian pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Egyptian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Egypt.
Exploit The Latest Competitive Egyptian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Egypt.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism;
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Executive Summary
The Sector At A Glance
Key Insights On The Pharmaceutical Sector Of Egypt
Egypt’s drug market was worth US$1.14bn in 2005 and is one of the largest in the Middle East and North Africa (MENA) region. However, BMI predicts that growth will be sluggish over the forecast period with expenditure on pharmaceuticals reaching US$1.47bn by 2010. Despite enacting a number of reforms to its business environment in recent years, the most important being the introduction of the World Trade Organisation (WTO)’s Trade Related Aspects of Intellectual Property Rights (TRIPS) legislation, a number of barriers to investment remain.
Possibly the most controversial is the government’s stringent pricing system, which effectively means that no high-price medicines can be sold on the market. As well as discouraging multinational activity, this policy also has the effect of starving the Egyptian public of the latest drug technologies. Because no price increases are permitted for inflation, local producers are also suffering and increasingly looking to export pharmaceutical to less regulated markets.
Yet, BMI is optimistic that government inflexibility on pricing matters will lessen in the coming years, as it attempts to promote business interests in the country. Although it is keen to maintain affordable medicines for the population, it must also provide sufficient incentives for private pharmaceutical production. The signs look promising, and recently the state has allowed the partial privatisation of a number of publicly owned pharmaceutical companies, organised under the umbrella group the Holding Company for Pharmaceuticals.
Also, foreign investors seem to be interested in the drug market, attracted by the country’s rapidly expanding population and the wide scope for development - per capita health expenditure was only US$15.3 in 2005. Recently, a US consortium completed the purchase of a 93% stake in pharmaceutical company Amoun for US$454mn, in one of the biggest private equity investments ever in Egypt.
BMI’s adjusted Business Environment Rankings for the MENA region reveal that Egypt is in 10th place ahead of Lebanon, Iran, Nigeria and Zimbabwe. This is primarily due to ongoing issues with intellectual property and government intervention in the drug sector. However, if market reforms continue at the current pace, Egypt should climb the leader board because the country has much untapped potential
For more information, Please visit :
http://www.bharatbook.com/
